DETECT III: a multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients (pts) with initially HER2-negative metastatic breast cancer but with HER2-positive circulating tumor cells (CTC) - Hagenbeck, C; Melcher, C A; Janni, J W (J Clin Oncol, 2012)
(Suppl.): Abstr. TPS1146